Vaccinogen Selects Clinipace Inc. Worldwide to Manage Global Phase 3b Clinical Trial

Published: May 05, 2010

MORRISVILLE, N.C.--(BUSINESS WIRE)--Clinipace Worldwide, a global full-service clinical research organization (CRO), announced today that Vaccinogen, a biotechnology company with more than three decades experience researching how to combat cancer using the body’s own immune system, has selected the company to manage a pivotal phase 3b confirmatory trial for OncoVAX® in the treatment of Stage II Colon Cancer.

Back to news